Patient characteristics
| Patient ID | Age (years) | Gender | Smoking status (pack-year) | HPV status | PD-L1 CPS | PD-L1 TPS | Primary location | Clinical TNM | Sitravatinib (days) | Nivolumab dosed | Surgery within window | Pathologic TNM | PTR (% of viable tumor) | Margins (>5 mm) | ENE | PORT |
| S-001 | 58 | Male | Never | Negative | >20 | >50 | Alveolus | cT4aN2b | 21 | Yes | Yes | ypT0N0 | cPR (0) | Negative | No | Yes |
| S-002 | 58 | Female | Never | Negative | >20 | >50 | Alveolus | cT4aN2b | 21 | Yes | Yes | ypT4aN0* | mPR (<10) | Negative | No | Yes |
| S-004 | 59 | Male | Current (30) | Negative | >20 | 1–50 | Tongue | cT3N1 | 28 | Yes | Yes | ypT2N0 | iPR (65) | Negative | No | Yes |
| S-006 | 59 | Male | Former (40) | Negative | >20 | 1–50 | Tongue | cT3N1 | 21 | Yes | Yes | ypT3N1 | iPR (36) | Negative | No | Yes |
| S-007 | 63 | Male | Current (50) | Negative | <1 | <1 | Floor of mouth | cT4aN2c | 21 | Yes | Yes | ypT4aN0 | iPR (94) | Negative | No | Yes |
| S-008 | 60 | Male | Former (30) | Negative | 1–20 | 1–50 | Tongue | cT2N0 | 21 | Yes | Yes | ypT1pN0 | iPR (100)† | Negative | No | No |
| S-009 | 71 | Female | Never | Negative | >20 | 1–50 | Alveolus | cT4aN1 | 15 | Yes | No | ypT3pN0 | iPR (95) | Negative | No | Yes |
| S-010 | 68 | Male | Former (20) | Positive | 1–20 | 1–50 | Tongue | cT2N2b | 28 | Yes | Yes | ypT1pN2a | iPR (38) | Negative | No | Yes |
| S-011 | 50 | Male | Current (40) | Negative | 1–20 | <1 | Tongue | cT3N0 | 28 | Yes | Yes | ypT1pN1 | iPR (87) | Negative | No | Yes |
| S-013 | 53 | Male | Never | Negative | >20 | 1–50 | Alveolus | cT4aN0 | 28 | Yes | Yes | ypT2pN0‡ | mPR (<10) | Negative | No | Yes |
*No invasive squamous cell carcinoma found in the mucosa, only remaining focis in the bone.
†iPR (100): this patient’s surgical specimen had residual viable tumor in all the areas evaluated.
‡Prominent lymphohistiocytic inflammatory infiltrate with multiple giant cells and cholesterol cleft, which involve the soft tissue underneath the mucosa extensively. Remaining 1 cm tumor is also heavily ulcerated with prominent inflammatory infiltrate.
CPS, combined positive score; ENE, extranodal extension; HPV, human papillomavirus; ID, identification; PD-L1, programmed ligand-1; PORT, postoperative radiotherapy; PTR, pathological treatment response; TNM, tumor-node-metastasis classification; TPS, tumor positive score.